振德医疗
(603301)
| 流通市值：52.17亿 | | | 总市值：52.17亿 |
| 流通股本：2.66亿 | | | 总股本：2.66亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 991,564,852.44 | 4,263,886,317.39 | 3,125,390,090.31 | 2,042,419,723.69 |
| 营业收入 | 991,564,852.44 | 4,263,886,317.39 | 3,125,390,090.31 | 2,042,419,723.69 |
| 二、营业总成本 | 932,157,374.02 | 3,861,780,274.2 | 2,833,455,972.78 | 1,832,891,465.75 |
| 营业成本 | 651,676,946.14 | 2,813,364,026.6 | 2,036,380,225.14 | 1,319,157,578.63 |
| 税金及附加 | 15,783,153.35 | 40,298,036.99 | 29,635,314.02 | 20,610,507.08 |
| 销售费用 | 90,949,436.83 | 368,569,318.44 | 260,251,647.85 | 178,665,100.37 |
| 管理费用 | 134,010,474.36 | 521,609,860.99 | 394,925,025.94 | 262,769,885.49 |
| 研发费用 | 33,484,212.15 | 135,489,953.88 | 98,872,971.89 | 62,452,317.21 |
| 财务费用 | 6,253,151.19 | -17,550,922.7 | 13,390,787.94 | -10,763,923.03 |
| 其中:利息费用 | 5,406,465.13 | 28,733,061.81 | 23,927,495.58 | 16,400,517.1 |
| 其中:利息收入 | 1,769,372.4 | 24,851,303.05 | 21,746,194.32 | 16,480,612.8 |
| 加:公允价值变动收益 | 3,509,377.37 | -12,245,552.1 | -2,915,353.67 | -926,628.78 |
| 加:投资收益 | -709,582.43 | 11,073,234.7 | 8,575,281.52 | 1,274,897.18 |
| 资产处置收益 | -4,999.99 | 93,432,002.11 | 99,294,084.87 | 87,995.24 |
| 资产减值损失(新) | -10,188,142.92 | -41,817,004.2 | -26,131,509.05 | -22,005,732.22 |
| 信用减值损失(新) | 552,909.45 | -10,231,447.63 | -9,965,400.43 | -9,397,417.34 |
| 其他收益 | 9,940,931.7 | 49,478,535.27 | 35,095,066.37 | 22,694,951.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 62,507,971.6 | 491,795,811.34 | 395,886,287.14 | 201,256,323.06 |
| 加:营业外收入 | 12,078.22 | 571,817.86 | 356,965.54 | 20,121.8 |
| 减:营业外支出 | 1,126,168.67 | 16,909,056.54 | 15,423,812.13 | 3,452,759.36 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 61,393,881.15 | 475,458,572.66 | 380,819,440.55 | 197,823,685.5 |
| 减:所得税费用 | 8,986,096.79 | 78,247,705.23 | 63,345,085.69 | 30,536,089.17 |
| 六、净利润 | 52,407,784.36 | 397,210,867.43 | 317,474,354.86 | 167,287,596.33 |
| 持续经营净利润 | 52,407,784.36 | 397,210,867.43 | 317,474,354.86 | 167,287,596.33 |
| 归属于母公司股东的净利润 | 51,241,871.64 | 385,170,721.28 | 307,460,239.15 | 161,109,105.3 |
| 少数股东损益 | 1,165,912.72 | 12,040,146.15 | 10,014,115.71 | 6,178,491.03 |
| (一)基本每股收益 | 0.19 | 1.45 | 1.15 | 0.6 |
| (二)稀释每股收益 | 0.19 | 1.45 | 1.15 | 0.6 |
| 八、其他综合收益 | 21,956,580.28 | 27,660,473.42 | 49,566,938.58 | 35,850,865.24 |
| 归属于母公司股东的其他综合收益 | 13,501,740.97 | 26,652,443.29 | 42,163,042.24 | 36,081,159.49 |
| 九、综合收益总额 | 74,364,364.64 | 424,871,340.85 | 367,041,293.44 | 203,138,461.57 |
| 归属于母公司股东的综合收益总额 | 64,743,612.61 | 411,823,164.57 | 349,623,281.39 | 197,190,264.79 |
| 归属于少数股东的综合收益总额 | 9,620,752.03 | 13,048,176.28 | 17,418,012.05 | 5,948,196.78 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |